BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Ocugen, Union Pacific

Reuters
Yesterday
BUZZ-U.S. STOCKS ON THE MOVE-<a href="https://laohu8.com/S/TSLA">Tesla</a>, <a href="https://laohu8.com/S/OCGN">Ocugen</a>, Union Pacific

Eikon search string for individual stock moves: STXBZ

The Day Ahead newsletter: https://refini.tv/3LI4BU7

The Morning News Call newsletter: https://refini.tv/3dKUyB8

U.S. stock index futures were muted on Monday, setting a cautious tone for a crucial week in which the Federal Reserve is widely expected to resume its interest rate cutting cycle, while Tesla rose after CEO Elon Musk's share purchase. .N

** Alibaba.com Ltd <BABA.N>:

** Trip.com Group Ltd <TCOM.O>:

BUZZ - HK shares at nearly 4-year peak on sector outlook optimism nL2N3V203L

** Nvidia Corp <NVDA.O>:BUZZ - Falls after China says it violated anti-monopoly law nL3N3V20EP

** Timken Co <TKR.N>:BUZZ - JPM initiates Timken at 'neutral', seeing balanced near-term risk and reward nL3N3V20FY

** Phillips 66 <PSX.N>:BUZZ - Jefferies raises PT on Phillips 66 over deal with Cenovus Energy nL3N3V20GQ

** NextDecade Corp <NEXT.O>:BUZZ - TD Cowen cuts NextDecade to 'hold' on financing, margin risks nL3N3V20GV

** Avita Medical Inc <RCEL.O>:BUZZ - Climbs after European nod for wound care device nL3N3V20I6

** Hims & Hers Health Inc <HIMS.N>:BUZZ - Down after US FDA chief says super bowl ad violated drug promotion rules nL3N3V20I5

** Tesla Inc <TSLA.O>:BUZZ - Jumps as Musk buys 2.57 million shares nL3N3V20IJ

** Eversource Energy <ES.N>:BUZZ - Jefferies raises PT on Eversource Energy, retains 'underperform' rating nL3N3V20HM

** Ocugen Inc <OCGN.O>:BUZZ - Up after licensing deal for ophthalmic gene therapy in South Korea nL3N3V20J5

** Permian Resources Corp <PR.N>:BUZZ - Slips after launching secondary offering nL6N3V20CG

** VF Corp <VFC.N>:BUZZ - To sell Dickies for $600 million, shares rise nL6N3V20CX

** Union Pacific Corp <UNP.N>:BUZZ - Shares rise after Citigroup hikes rating to 'buy' nL3N3V20K6

** Monte Rosa Therapeutics Inc <GLUE.O>:BUZZ - Soars after $5.7 billion drug development deal with Novartis nL3N3V20KM

(Compiled by Rajarshi Roy and Sahil Pandey)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10